Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,600 across all filing types
Latest filing 2024-07-02 AGM Information
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
113年年報及股東會資料 — 2024_1734_20240619FE2.pdf
AGM Information Classification · 100% confidence The document is a detailed agenda and materials for the 2024 Annual Shareholders' Meeting of Sinphar Pharmaceutical Co., Ltd. It includes meeting procedures, agenda items such as company reports, ratifications, discussions, elections, and other proposals. It also contains attachments like the 2023 Business Report, Audit Committee’s Review Report, 2023 Financial Statements, amendments to board meeting rules, endorsements and guarantees, and list of director candidates. The presence of voting results and detailed shareholder meeting content indicates this is related to the Annual General Meeting (AGM). The document is not just an announcement but contains substantive meeting materials and reports typically shared at an AGM. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-07-02 Chinese
113年年報及股東會資料 — 2024_1734_20240619FE1.pdf
AGM Information Classification · 100% confidence The document is a notice for the 2024 Annual Shareholders' Meeting of Sinphar Pharmaceutical Co., Ltd. It includes the meeting agenda, company reports to be presented, ratifications to be made, discussions, elections of directors, and other proposals. It also provides detailed information about candidates for directors and independent directors, as well as information on the release of prohibition on directors from participation in competitive business. The document is clearly a meeting notice and not the actual annual report or financial statements. It is not a report publication announcement because it contains substantive meeting agenda and candidate information rather than just a brief announcement or link. Therefore, this document fits the category of AGM Information (AGM-R).
2024-07-02 Chinese
113年年報及股東會資料 — 2024_1734_20240619F02.pdf
AGM Information Classification · 100% confidence The document is a detailed record of a company's Annual General Meeting (AGM) including the meeting agenda, reports, approvals, discussions, elections, and other shareholder matters. It contains the full text of the meeting proceedings, including the business report, audit committee report, financial statements, dividend distribution, election of directors, and other corporate governance matters. The presence of detailed meeting procedures, agenda items, and voting results indicates this is the actual AGM materials rather than a simple announcement or summary. The document length is substantial (15,000 characters), and it includes substantive content typical of AGM Information filings. Therefore, the document is best classified as AGM Information (AGM-R).
2024-07-02 Chinese
113年年報及股東會資料 — 2024_1734_20240619F13.pdf
AGM Information Classification · 95% confidence The document is titled as reference materials for the 113th Annual General Meeting (AGM) of 杏輝藥品工業股份有限公司. It contains detailed agenda items typical of an AGM, including approval of the annual business report and financial statements for the 112th fiscal year, dividend distribution proposals, capital increase proposals, election of directors, and other shareholder meeting matters. The content includes resolutions, explanations, and election results, which are all typical materials presented and discussed during an AGM. The document is not a full annual report or financial statement itself but rather the materials for the shareholders' meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length is about 5,390 characters, consistent with detailed AGM materials rather than a brief announcement or a full annual report.
2024-07-02 Chinese
113年年報及股東會資料 — 2024_1734_20240619F01.pdf
Regulatory Filings
2024-07-02 Chinese
功能性委員會成員
Regulatory Filings Classification · 90% confidence The document is very short (236 characters) and contains a table with company code, company name, establishment date, and member list. It appears to be a basic disclosure of company information or board members but lacks any detailed financial data, report content, or announcements of voting results. There is no indication of a full report, financial statements, or regulatory filings. Given the brevity and nature of the content, it does not fit into detailed report categories like Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It also does not announce voting results or changes in management explicitly. The document is more of a general regulatory disclosure or company information update. According to the rules, such brief and general disclosures that do not fit other categories should be classified as Regulatory Filings (RNS).
2024-06-28 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.